March 14 2018

**US Securities & Exchange Commission** Office of FOIA and Privacy Act Operations 100 F Street, NE Mail Stop 5100 Washington, DC 20549-5100



Dear FOIA Office:

Under the Freedom of Information Act (FOIA), please send a copy of the following:

A copy of: Exhibit 10.69 to the form 10-K filed by JAZZ PHARMACEUTICALS INC on March 31, 2008 In the event confidential treatment has not expired provide the specific date for which confidential treatment is still in effect. I do not need a copy of the order. We authorize up to \$61.00 in processing fees. Thank You,

Paul D'Souza Editor - Deals

Clarivate Analytics Friars House, 160 Blackfriars Road London, UK SE1 8EZ Phone: +44-2074334789 paul.dsouza@clarivate.com



## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATION PLACE 100 F STREET, NE WASHINGTON, DC 20549-2465

Office of FOIA Services

April 9, 2018

Mr. Paul D'Souza Clarivate Analytics 160 Blackfriars Road London, UK SE18EZ

RE: Freedom of Information Act (FOIA), 5 U.S.C. § 552

Request No. 18-03275-E

Dear Mr. D'Souza:

This letter is in response to your request, dated and received in this Office on March 14, 2018, for a copy of Exhibit 10.69 to the Form 10-K by Jazz Pharmaceuticals, Inc. on March 31, 2008.

The Commission extended confidential treatment to Exhibit 10.69 to the Form 10-K under Rule 24b-2 of the Securities Exchange Act of 1934 through March 27, 2020. Since confidential treatment has been extended, we are providing the expiration date from the relevant CT order as requested.

If you have any questions, please contact me directly at <a href="mailto:andersonc@sec.gov">andersonc@sec.gov</a> or (202) 551-8315. You may also contact me at <a href="mailto:foiapa@sec.gov">foiapa@sec.gov</a> or (202) 551-7900. You also have the right to seek assistance from a FOIA Public Liaison, Ray J. McInerney at (202) 551-7900.

Sincerely,

Clarissa Anderson FOIA Research Specialist

Clarissa Anderson